< Back to previous page

Project

Prognostic and predictive biomarker analysis in mCRC KRAS wild type patients treated in first line with Erbitux (Cetixumab) in combination with standard chemotherapy in daily clinical practice in Belgium.

This project represents a formal research agreement between UA and on the other hand UZA. UA provides UZA research results mentioned in the title of the project under the conditions as stipulated in this contract.
Date:1 Sep 2013 →  31 Aug 2017
Keywords:CHEMOTHERAPY, BIOMARKER, ONCOLOGY
Disciplines:Morphological sciences, Oncology